36 structural-engineering-"https:"-"https:"-"https:"-"https:"-"https:"-"UCL" positions at City of Hope
Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
spoken and written. Preferred qualifications: · M.S. with a background and profound knowledge in the field of either molecular biology, immunology, experience in sequencing, or protein structural
-
initiatives in translational imaging, drug development, radiation response, immunotherapy, and multiparametric quantitative imaging. · Maintain a forward-looking technology roadmap to ensure timely
-
are developing a series of new projects that integrate recent advances in deep-learning for structural biology (AlphaFold and generative approaches). We are seeking a bioinformatician to drive this cutting-edge
-
the management and implementation of departmental programs and goals that support the strategic plan for patient care services and the organization. Supports departmental implementation of new technology and
-
. As a successful candidate, you will: Operational Strategy & Leadership Oversee systemwide implementation of standardized workflows, technology integration, and operational processes that support
-
technology and services. Assures satisfaction of patients, physicians and other customers with care and services that are delivered. Develops and fosters collaborative relationships with other departments
-
immunotherapy through engineered CAR T and/or CAR NK cells, oncolytic virotherapy, antibody development, stem cell (including iPSCs) research, depending on the individual’s interests and strengths. Under general
-
with safety protocols and guidelines established by the FDA and the American College of Radiology. Your qualifications should include: Bachelor’s degree in Biomedical Engineering, Computer Science, or a
-
edge technology, research and clinical immunotherapeutic programs. New personnel will be trained in project specific techniques and procedures. As a successful candidate, you will: · Manufacture
-
: · Contribute to the development of CD38 antibody‑drug conjugates (ADCs) and other multiple myeloma targets, including monoclonal antibody (mAb) engineering, ADC conjugation, biophysical characterization (SPR